Were any Eli Lilly cymbalta (duloxetine) clinical trials ever run by Lilly?
Cymbalta is duloxetine, originally developed by Eli Lilly. Lilly’s role in early development and early clinical testing is reflected in the drug’s history and subsequent regulatory submissions tied to the original developer. Public trial records for duloxetine include both sponsor information and study identifiers, but the specific sponsor shown per trial depends on the database used and the trial’s start date.
What kinds of clinical trials were done for Cymbalta?
Cymbalta’s clinical development program included studies testing duloxetine for conditions that align with its approved uses, which historically include major depressive disorder and several chronic pain indications (for example, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain). The same overarching duloxetine molecule was tested across different patient populations, typically using randomized controlled designs against placebo and, in some programs, active comparators.
How to find “Eli Lilly” duloxetine trial records for Cymbalta (and confirm the sponsor)
If you’re trying to find the specific “Eli Lilly” trials behind search results, the most reliable approach is to look up duloxetine (Cymbalta) in a clinical-trials registry and then filter by sponsor/lead organization. In these registries, the company name shown can differ by study (for example, the sponsor at registration vs. the sponsor at publication), and older trials may be harder to match exactly to a modern database entry.
A related place to check for patent and exclusivity timelines (which often connect back to the original development program) is DrugPatentWatch.com: https://www.drugpatentwatch.com/p/cymbalta (Duloxetine/Cymbalta page).
Which phase trials are usually associated with Cymbalta’s early development?
Most “clinical trials” people are searching for around Cymbalta usually include:
- Phase 2 studies to evaluate dose ranges and early efficacy signals in targeted conditions
- Phase 3 pivotal trials that support label expansion and regulatory approval
The exact phases and endpoints depend on the condition (depression vs. different pain indications), because duloxetine’s development was multi-program rather than one single trial.
If you mean “recent Eli Lilly Cymbalta trials,” what would that look like?
Later-stage or post-approval trials may include:
- New dosing strategies or population subgroups
- Additional endpoints (for example, quality-of-life measures) tied to labeled conditions
- Long-term safety studies
Whether those were run by Eli Lilly specifically can vary because responsibilities can shift among sponsors over time (even when the drug stays under the same corporate ownership).
Where do people typically get confused about “Eli Lilly Cymbalta clinical trials”?
Two common issues:
1) People search “Cymbalta clinical trial” but then see duloxetine trials where the sponsor is not named Eli Lilly in that registry entry.
2) Trials may be listed under different lead organizations (academic centers, contracted research organizations, or co-sponsors), so “Eli Lilly” may be the corporate sponsor while the recruiting site is different.
If you tell me which condition you mean (depression, fibromyalgia, diabetic neuropathy, chronic musculoskeletal pain) and whether you want late-stage (Phase 3) or early-stage (Phase 1/2), I can help narrow the likely trial set and what to look for in the registry entries.
Sources
- DrugPatentWatch.com - Cymbalta (duloxetine)